BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kapadia SN, Marks KM. Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. Clin Ther 2018;40:1234-45. [PMID: 29983266 DOI: 10.1016/j.clinthera.2018.05.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Du P, Wang X, Kong L, Riley T 3rd, Jung J. Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017. Am J Prev Med 2021;60:285-93. [PMID: 33221144 DOI: 10.1016/j.amepre.2020.08.031] [Reference Citation Analysis]
2 Sherbuk JE, McManus KA, Kemp Knick T, Canan CE, Flickinger T, Dillingham R. Disparities in Hepatitis C Linkage to Care in the Direct Acting Antiviral Era: Findings From a Referral Clinic With an Embedded Nurse Navigator Model. Front Public Health 2019;7:362. [PMID: 31828056 DOI: 10.3389/fpubh.2019.00362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
3 Du P, Yin X, Kong L, Jung J. A Telementoring Program and Hepatitis C Virus Care in Rural Patients. Telemed Rep 2021;2:143-7. [PMID: 34041510 DOI: 10.1089/tmr.2021.0001] [Reference Citation Analysis]
4 Asker B, Jawad R, Asreah R, Jamal H, Jassem A, Inaya MA, Baker HA, Kozma S, Mansour E, McNamara B, Miller R, Darlington O, McEwan P, Sugrue DM, Jarallah H. Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment. Pharmacoeconomics 2021. [PMID: 34396494 DOI: 10.1007/s40273-021-01064-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ward JW, Hinman AR. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats. Gastroenterology. 2019;156:297-310. [PMID: 30391470 DOI: 10.1053/j.gastro.2018.10.048] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
6 Kapadia SN, Johnson P, Schackman BR, Bao Y. Hepatitis C Treatment Uptake by New Prescribers After the Introduction of Direct Acting Antivirals. J Gen Intern Med 2020;35:975-7. [PMID: 31325131 DOI: 10.1007/s11606-019-05200-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Cole AM, Keppel GA, Baldwin LM, Gilles R, Holmes J, Vance C, Kriesgman B, Linares A, Hornecker J, Paddock E, Gerrish W, Alto W, Gould D, Neher J. Room for Improvement: Rates of Birth Cohort Hepatitis C Screening in Primary Care Practices-A WWAMI Region Practice and Research Network Study. J Prim Care Community Health 2019;10:2150132719884298. [PMID: 31658872 DOI: 10.1177/2150132719884298] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Pandey M, Konrad S, Reed N, Ahenakew V, Isbister P, Isbister T, Gallagher L, Campbell T, Skinner S. Liver health events: an indigenous community-led model to enhance HCV screening and linkage to care. Health Promot Int 2021:daab074. [PMID: 34125199 DOI: 10.1093/heapro/daab074] [Reference Citation Analysis]
9 Jhaveri R. Hot Topics in Viral Infections. Clin Ther 2018;40:1230-3. [PMID: 30093134 DOI: 10.1016/j.clinthera.2018.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Roblero JP, Arab JP, Mezzano G, Mendizabal M. Hepatitis C Virus Infection: What Are We Currently Doing in Latin America About WHO's Proposals for 2030? Clin Liver Dis (Hoboken) 2021;18:72-5. [PMID: 34584671 DOI: 10.1002/cld.1084] [Reference Citation Analysis]
11 Sherbuk JE, Tabackman A, McManus KA, Kemp Knick T, Schexnayder J, Flickinger TE, Dillingham R. A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South. Harm Reduct J 2020;17:64. [PMID: 32948189 DOI: 10.1186/s12954-020-00409-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Shader RI. Zoonotic Viruses: The Mysterious Leap From Animals to Man. Clin Ther 2018;40:1225-7. [PMID: 30055823 DOI: 10.1016/j.clinthera.2018.06.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Du P, Wang X, Kong L, Jung J. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents? Telemed J E Health. 2021;27:488-494. [PMID: 32882154 DOI: 10.1089/tmj.2020.0090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Portari-Filho LH, Álvares-da-Silva MR, Gonzalez A, Ferreira AP, Villela-Nogueira CA, Mendes-Correa MC, Lima JM, Lopes EP, Brandão CE, Ivantes C, Lyra A, Lindenberg A, Ferraz ML. How are HCV-infected patients being identified in Brazil: a multicenter study. Braz J Infect Dis 2019;23:34-9. [PMID: 30849332 DOI: 10.1016/j.bjid.2019.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Kapadia SN, Johnson P, Marks KM, Schackman BR, Bao Y. Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era. Med Care 2021;59:795-800. [PMID: 34081676 DOI: 10.1097/MLR.0000000000001573] [Reference Citation Analysis]
16 Torrens M, Soyemi T, Bowman D, Schatz E. Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment. BMC Infect Dis 2020;20:702. [PMID: 32972393 DOI: 10.1186/s12879-020-05426-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dhiman RK, Grover GS, Premkumar M. Hepatitis C elimination: a Public Health Perspective. Curr Treat Options Gastro 2019;17:367-77. [DOI: 10.1007/s11938-019-00240-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
18 Norton BL, Litwin AH. A Call to Action: HCV Treatment of People Who Inject Drugs in the United States. Clin Infect Dis 2020;70:2366-8. [PMID: 31513706 DOI: 10.1093/cid/ciz701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
20 Forns X, Feld JJ, Dylla DE, Pol S, Chayama K, Hou J, Heo J, Lampertico P, Brown A, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Gordon SC, Jacobson IM. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. Adv Ther 2021;38:3409-26. [PMID: 34021887 DOI: 10.1007/s12325-021-01753-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Agi E, Asghari S, Namvar A, Khairkhah N, Naderi N, Anvar A, Azizi Saraji A, Bolhassani A; Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents. JoMMID 2020;8:1-6. [DOI: 10.29252/jommid.8.1.1] [Reference Citation Analysis]
22 Lau AA, Strebe JK, Sura TV, Hansen LA, Jain MK. Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow‐up. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.645] [Reference Citation Analysis]
23 Seaman A, King CA, Kaser T, Geduldig A, Ronan W, Cook R, Chan B, Levander XA, Priest KC, Korthuis PT. A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment. Int J Drug Policy 2021;:103359. [PMID: 34325969 DOI: 10.1016/j.drugpo.2021.103359] [Reference Citation Analysis]